Company Description
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States.
Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study.
The company develops ORIC-533, an orally bioavailable small molecule inhibitor of CD73; and ORIC-613, a small molecule therapeutic intended to address a mechanism of innate resistance found in a subset of breast cancers.
It has clinical development collaboration agreement for a potential Phase 2 study of ORIC-533 in multiple myeloma with Pfizer Inc.; a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor.
The company was incorporated in 2014 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2014 |
| IPO Date | Apr 24, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 115 |
| CEO | Jacob Chacko |
Contact Details
Address: 240 East Grand Avenue, 2nd Floor South San Francisco, California 94080 United States | |
| Phone | 650 388 5600 |
| Website | oricpharma.com |
Stock Details
| Ticker Symbol | ORIC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001796280 |
| CUSIP Number | 68622P109 |
| ISIN Number | US68622P1093 |
| Employer ID | 47-1787157 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jacob M. Chacko M.B.A., M.D. | President, Chief Executive Officer and Director |
| Dr. Richard A. Heyman Ph.D. | Co-Founder, Independent Chairman and Member of Scientific Advisory Board |
| Dominic G. Piscitelli CPA, M.B.A. | Chief Financial Officer |
| Dr. Pratik S. Multani M.D., M.S. | Chief Medical Officer |
| Dr. Charles L. Sawyers B.A., M.D., Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Dr. Scott W. Lowe Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Dr. Lori Sickels Friedman Ph.D. | Chief Scientific Officer |
| Dr. Christian V. Kuhlen Esq., J.D., M.D. | General Counsel |
| Daniel Iazzetti | Vice President and Head of People |
| Dr. Edna Chow Maneval Ph.D. | Executive Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2025 | ARS | Filing |
| Apr 23, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 20, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 14, 2025 | 8-K | Current Report |
| Feb 25, 2025 | 8-K | Current Report |
| Feb 18, 2025 | 10-K | Annual Report |
| Feb 18, 2025 | 8-K | Current Report |
| Feb 12, 2025 | SCHEDULE 13G/A | Filing |
| Jan 13, 2025 | 8-K | Current Report |